IICT, Lee Pharma collaborate for synthesis of 2-DG

The collaboration between IICT and Lee Pharma is expected to provide alternatives of cheaper therapeutics against Covid-19.

Hyderabad: In yet another affordable treatment option for patients against Covid-19, Hyderabad-based Indian Institute of Chemical Technology (IICT) has entered into a non-exclusive licensing agreement with Lee Pharma for synthesis of 2-Deoxy-D-Glucose (2-DG). The collaboration between IICT and Lee Pharma is expected to provide alternatives of cheaper therapeutics against Covid-19.

Just a few days ago, the Defense Research and Development Organisation (DRDO) in collaboration with Dr Reddy’s Laboratories had launched 2-DG as an adjunct in treatment of moderate to severe Covid-19 patients. In a limited study that involved about 200 patients, the 2-DG drug, which will be available in the form of sachets, was found to help speed-up recovery and reduce oxygen dependence. The DRDO 2-DG drug, which will cost close to Rs 900 per sachet, has been launched by Dr Reddy’s laboratories.

---

The Lee Pharma is expected to approach the Drug Controller General of India (DCGI) for the approval of its 2-DG formulation. According to reports, Lee Pharma will manufacture and commercialise the 2-DG sachets from their formulation facility located at SEZ, Duvvada, Visakhapatnam in AP.

The Director of CSIR-IICT, Dr S Chandrashekhar, who was quoted by news agencies, said that the agreement with Lee Pharma will help in providing affordable therapeutic options for treatment of Covid-19. Raghumitra Alla, Director, Lee Pharma said, “The collaboration with IICT for 2-DG API is part of our broader strategy for enhancing Covid-19 treatment options.”